The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritis

Clinical Therapeutics

Volumn 21, Issue 10, 1999, Pages 1688-1702

  Schnitzer, Thomas J ^a   Truitt, Ken ^b   Fleischmann, Roy ^c   Dalgin, Paul ^d   Block, Joel ^e   Zeng, Qi ^b   Bolognese, James ^b   Seidenberg, Beth ^b   Ehrich, Elliot W ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c METROPLEX CLINICAL RESEARCH CENTER   (United States)

^d Stamford Therapeutics Consortium   (United States)

^e RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

COX 2 specific inhibitors; Cyclooxygenase; Rheumatoid arthritis; Rofecoxib

Indexed keywords

ANTIMALARIAL AGENT; AZATHIOPRINE; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; GOLD; METHOTREXATE; PENICILLAMINE; ROFECOXIB; SALAZOSULFAPYRIDINE; TETRACYCLINE DERIVATIVE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; DYSPEPSIA; FEMALE; HEADACHE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PAIN ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; RASH; RHEUMATOID ARTHRITIS; SINUSITIS; VERTIGO;

EID: 0032744460     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(99)80048-4     Document Type: Article

References (51)

1. 1. ACR Clinical Guidelines Committee. Guidelines for the management of rheumatoid arthritis. Arthritis Rheum. 1996;39:713-722.
2. 2. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action of aspirin-like drugs. Nat New Biol. 1971;231:232-235.
3. 3. Smith JB, Willis AL. Aspirin selectivity inhibits prostaglandin production in human platelets. Nat New Biol. 1971;231: 235-237.
4. 4. Sirios J, Simmons DL, Richards J. Hormonal regulation of messenger ribonucleic acid encoding a novel isoform of prostaglandin endoperoxide H synthase in rat pre-ovulatory follicles. Induction in vivo and in vitro. J Biol Chem. 1992;267:11586-11592.
5. 5. Kujubu DA, Fletcher BS, Varnum BC, et al. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J Biol Chem. 1991;266:2866-2872.
6. 6. Xie WL, Chipman JG, Robertson DL, et al. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci USA. 1991;88:2692-2696.
7. 7. O'Banion MK, Winn VD, Young DA. cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase. Proc Natl Acad Sci USA. 1992;89:4888-4892.
8. 8. Jones DA, Carlton DP, McIntyre TM, et al. Molecular cloning of human prostaglandin endoperoxide synthase type II and demonstration of expression in response to cytokines. J Biol Chem. 1993;268:9049-9054.
9. 9. Luong C, Miller A, Barnett J, et al. Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2. Nat Struct Biol. 1996;11:927-933.
10. 10. Kurumbail RG, Stevens AM, Gierse JK, et al. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature. 1996;384:644-647.
11. 11. Vane JR, Botting RM. Anti-inflammatory drugs and their mechanism of action. Inflamm Res. 1998;47(Suppl 2):S78-S87.
12. 12. Whittle BJR, Higgs GA, Eakins KE, et al. Selective inhibition of prostaglandin production in inflammatory exudates and gastric mucosa. Nature. 1980;284:271-273.
13. 13. Moncada S, Gryglewski R, Bunting S, Vane JR. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature. 1976;263:663-665.
14. 14. Walenga RW, Kester M, Coroneos E, et al. Constitutive expression of prostaglandin endoperoxide G/H synthetase (PGHS)-2 but not PGHS-1 in human tracheal epithelial cells in vitro. Prostaglandins. 1996;52:341-359.
15. 15. Akarasereenont P, Mitchell JA, Appleton I, et al. Involvement of tyrosine kinase in the induction of cyclo-oxygenase and nitric oxide synthase by endotoxin in cultured cells. Br J Pharmacol. 1994;113:1522-1528.
16. 16. Blanco A, Habib A, Levy-Toledano S, Maclouf J. Involvement of tyrosine kinases in the induction of cyclo-oxygenase-2 in human endothelial cells. Biochem J. 1995;312:419-423.
17. 17. Lyons-Giordano B, Pratta MA, Galbraith W, et al. Interleukin-1 differentially modulates chondrocyte expression of cyclo-oxygenase-2 and phospholipase A2. Exp Cell Res. 1993;206:58-62.
18. 18. Mitchell JA, Akarasereenont P, Thiemermann C, et al. Selectivity of nonsteroidal anti-inflammatory drugs as inhibitors of constitutive and inducible cyclo-oxygenase. Proc Natl Acad Sci USA. 1994; 90:11693-11697.
19. 19. Berenbaum F, Jacques C, Thomas G, et al. Synergistic effect of interleukin-1 β and tumor necrosis factor α or PGE2 production by articular chondrocytes does not involve PLA2 stimulation. Exp Cell Res. 1996;222:379-384.
20. 20. Siegle I, Klein R, Backman JT, et al. Expression of cyclooxygenase 1 and cyclooxygenase 2 in human synovial tissue: Differential elevation of cyclooxygenase 2 in inflammatory joint diseases. Arthritis Rheum. 1998;41:122-129.
21. 21. Seibert K, Masferrer JL. Role of inducible cyclooxygenase (COX-2) in inflammation. Receptor. 1994;4:17-23.
22. 22. Meade EA, Smith WL, deWitt DL. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J Biol Chem. 1993;268:6610-6614.
23. 23. Seibert K, Zhang Y, Leahy K, et al. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc Natl Acad Sci USA. 1994;91:12013-12017.
24. 24. Masferrer JL, Zweifel BS, Manning PT, et al. Selective inhibition of inducible cyclooxygenase 2 in vivo is anti-inflammatory and non-ulcerogenic. Proc Natl Acad Sci USA. 1994;91:3228-3232.
25. 25. Chan CC, Boyce S, Brideau C, et al. Pharmacology of a selective cyclooxygenase-2 inhibitor, L745.337 - a novel non-steroidal anti-inflammatory agent with an ulcerogenic sparing effect in rat and non-human primate stomach. J Pharmacol Exp Ther. 1995;273:1531-1537.
26. 26. Langman MJS, Weil J, Wainwright P, et al. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet. 1994;343:1075-1078.
27. 27. Fries JF. Assessing and understanding patient risk. Scand J Rheumatol Suppl. 1992;92:21-24.
28. 28. Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med. 1991;15:787-796.
29. 29. Hawkey CJ. COX-2 inhibitors. Lancet. 1999;353:307-314.
30. 30. Ehrich E, Dallob A, Van Hecken A, et al. Demonstration of selective COX-2 inhibition by MK-966 in humans. Arthritis Rheum. 1996:39(Suppl):S81. Abstract.
31. 31. Depre M, Ehrich C, De Lepeleire I, et al. Demonstration of COX-2 inhibition by MK-966 (Vioxx) in humans with supratherapeutic doses. Rheum Eur. 1998;27:196. Abstract.
32. 32. Saag K, Fisher C, McKay J, et al. MK-0966, a specific COX-2 inhibitor, has clinical efficacy comparable to ibuprofen in the treatment of knee and hip osteoarthritis (OA) in a 6 week controlled clinical trial. Arthritis Rheum. 1998;41(Suppl):A984. Abstract.
33. 33. Cannon G, Caldwell J, Holt P, et al. MK-0966, a specific COX-2 inhibitor, has clinical efficacy comparable to diclofenac in the treatment of knee and hip osteoarthritis (OA) in a 26 week controlled clinical trial. Arthritis Rheum. 1998;41(Suppl):A983. Abstract.
34. 34. Ehrich EW, Dallob AM, De Lepeleire I, et al. Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model. Clin Pharmacol Ther. 1999; 65:336-347.
35. 35. Morrison BW, Daniels SE, Kotey P, et al. Rofecoxib, a specific cyclooxygenase-2 inhibitor, in primary dysmenorrhea: A randomized controlled trial. Obstet Gynecol. In press.
36. 36. 1983 Metropolitan Height and Weight Tables. Stat Bull. 1983;64:3-9.
37. 37. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1996;39:723-731.
38. 38. Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995;38:727-735.
39. 39. Felson DT, Anderson JJ, Boers M, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum. 1993;36:729-740.
40. 40. Barr DR. Using confidence intervals to test hypotheses. J Qual Technol. 1969;1:256-258.
41. 41. Stein CM, Pincus T. Placebo-controlled studies in rheumatoid arthritis: Ethical issues. Lancet. 1999;353:400-403.
42. 42. Rochon PA, Binns MA, Litner JA, et al. Are randomized control trial outcomes influenced by the inclusion of a placebo group? A systematic review of non-steroidal antiinflammatory drug trials for arthritis treatment. J Clin Epidemiol. 1999; 52:113-122.
43. 43. Iqbal MP, Baig JA, Ali AA, et al. The effects of non-steroidal anti-inflammatory drugs on the disposition of methotrexate in patients with rheumatoid arthritis, Biopharm Drug Dispos. 1998;19:163-167.
44. 44. Davies NM, Anderson KE. Clinical pharmacokinetics of diclofenac. Clin Pharmacokinet. 1997;33:184-213.
45. 45. Tracy TS, Worster T, Bradley JD, et al. Methotrexate disposition following concomitant administration of ketoprofen, piroxicam and flurbiprofen in patients with rheumatoid arthritis. Br J Clin Pharmacol. 1994:37:453-456.
46. 46. Combe B, Edno L, Lafforgue P, et al. Total and free methotrexate pharmacokinetics with and without piroxicam in rheumatoid arthritis patients. Br J Rheumatol. 1995:34;421-428.
47. 47. Wallace CA, Bleyer A, Sherry DD, et al. Toxicity and serum levels of methotrexate in children with juvenile rheumatoid arthritis. Arthritis Rheum. 1989;32:677-681.
48. 48. ACR Ad Hoc Committee on Clinical Guidelines. Guidelines for monitoring drug therapy in rheumatoid arthritis. Arthritis Rheum. 1996;39:723-731.
49. 49. Bjarnason I, Sigthorsson G, Crane R, et al. COX-2 specific inhibition with MK-0966 25 or 50 mg qd does not increase intestinal permeability: A controlled study with placebo (PBO) and indomethacin 50 mg tid (INDO). Am J Gastroenterol. 1998;93:A246. Abstract.
50. 50. Hunt R, Bowen B, James C, et al. COX-2 specific inhibition with MK-0966 25 mg or 50 mg qd over 4 weeks does not increase fecal blood loss: A controlled study with placebo and ibuprofen 800 mg tid. Am J Gastroenterol. 1998;93:A247. Abstract.
51. 51. Whelton A, Hamilton CW. Nonsteroidal anti-inflammatory drugs: Effects on kidney function. J Clin Pharmacol. 1991;31:588-598.